March 15 (Reuters) – The U.S. government said on Wednesday it will subject 27 drugs to inflation penalties, a move that will require the pharmaceutical companies to pay Medicare rebates if they raise prices at a faster pace than the rise in inflation rate.
Under the new provisions, the government will start invoicing the companies for the rebates in 2025, but Medicare members will see a reduction in out-of-pocket costs starting April.
Here is a list of the drugs and companies:
($1 = 0.9217 Swiss francs)
Compiled by Aditya Samal and Leroy leo; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.
Read the full article here
